MRN posts 533% growth in first five years
pharmafile | August 1, 2012 | News story | Research and Development | clinical trials, growth, results
From humble beginnings in 2006 with six dedicated staff members and a vision to transform clinical trial support, the Medical Research Network (MRN) has seen phenomenal growth – with turnover for the year ending 2012 forecasted to be 700 per cent, and a near-fivefold increased in staff numbers.
In its first five years, MRN’s revenues have grown by 533 per cent and present forecasts predict a staggering 170 per cent increase on top of that by the end of this financial year, making it the world’s leading global provider of home healthcare for patients in clinical trials.
MRN was formed in November 2006 as a Management Buy Out from Healthcare at Home, led by Dr Graham Wylie, at the time Managing Director of Healthcare at Home’s Clinical Trials Division. The powerful mix of a deep need in clinical research for innovation to improve recruitment and retention and the instantly recognisable nature of the benefits of running clinical trials in the home to address this problem, coupled with the highly networked management team of the new company who between them now have over 80 years of experience has turned the organisation into a recognised global leader in its field.
MRN is a unique clinical trial support organisation offering nursing focussed patient and recruitment and retention solutions globally for clinical trials. Headquartered in the UK and now with a North American operation, the MRN offers Site Support and Home Trial Support services across the world and works with many of the largest Pharmaceutical and Biotech companies as well as Contract Research Organisations, plus specialist and niche companies with complex and specialized therapies under research.
With 28 full-time staff and several contract staff supporting HQ functions, as well as hundreds of nurses around the globe delivering services in four continents, the MRN plans continued expansion in the coming months to deliver its Home Trial Support and Site Nurse Support to a global audience.
MRN’s CEO, Dr Graham Wylie, attributes success to three main factors – service, support and above all, its staff, commenting: “The growth of the company has been driven by our commitment to meeting the needs of customers as they explore the benefits of MRN’s services requesting we work in more and more countries with increasingly large projects.
“With MRN’s services, customers continually see improvements in recruitment and retention of patients in their trials – two of the major challenges in Clinical Research today. Our ability to take the trial to the patient makes participation more convenient and appealing and boosts recruitment rates by over 60 per cent even in the simplest of trials. The reduction in the impact of the trial on the patient’s life is one of the few truly patient centric classes of services available for trials today, significantly improveing retention rates, which are consistently over 95 per cent in all projects we handle.
“Our service standards have been reviewed and tested by many customer audits as well as the MHRA and findings have been excellent. Our MHRA audit reported NO major findings and classed us as “low risk”, a result of which we are truly proud. At MRN we take quality very seriously and have a well-developed Quality Management System in place as well as a deeply embedded culture which follows our Vision & Values.
“Above all, the growth is due to our fantastic staff Stuart Redding, Paul Bodfish and Helena Baker – the original management team who made all this possible –, all our internal staff who work so hard to deliver our projects, and our partner organisations helping us deliver great nursing services, in particular Healthcare at Home whose CEO Mike Gordon has been a huge asset on our Board..
“I’d like to take this opportunity to thank everyone who has helped us make MRN the premier international business in our sector and we looked forward to continued growth as we achieve our ambition expansion plans.”
For more information on the MRN’s full range of services visit www.themrn.co.uk.
Related Content
Gilead and Merck share data from phase 2 trial of HIV treatment
Gilead Sciences and Merck (known as MSD outside of the US and Canada) have announced …
FDA clears Aruna Bio’s IND for AB126 to enter clinical trials
Aruna Bio has announced that the US Food and Drug Administration (FDA) has cleared its …
Genentech shares phase 3 results for ALK-positive early-stage lung cancer treatment
Roche’s Genentech has announced that the phase 3 ALINA trial assessing Alecensa, compared with platinum-based …
